Back

Diastolic reserve restoration drives functional improvement under mavacamten in obstructive hypertrophic cardiomyopathy: a real-world CPET–echocardiography study

29 August 2026 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Hypertrophic cardiomyopathy and the spectrum of left ventricular hypertrophy Systolic and Diastolic Function ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Julien Broustaille

Hospital Pontchaillou of Rennes, Rennes (France)

6 More presentations in this session

Presentation thumbnail
Atrial reverse remodelling and restored atrioventricular coupling define diastolic recovery during mavacamten therapy in obstructive hypertrophic cardiomyopathy
Doctor P. Craciun (Bucharest, RO) Miss S. Gonzalez De Alaiza (ES)
Abstract Slides Video
Presentation thumbnail
Predicting five-year mortality in patients with left ventricular hypertrophy based on dynamic radiomics from transthoracic echocardiography
Mr P. Su (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Sotatercept improves echocardiographic risk stratification in pulmonary arterial hypertension: real-world data from the french early access program
Doctor M. EL BLIDI (Le Kremlin-Bicetre, FR)
Abstract Slides Video
Presentation thumbnail
Systematic misclassification of left ventricular mass by echocardiography is driven by ventricular geometry: a CT-based reference analysis
Doctor S. Fathieh (London, GB)
Abstract Slides Video
Presentation thumbnail
Electrocardiographic markers of left atrial remodeling as predictors of diastolic dysfunction
Associate Professor L. Bikdelu (Mashhad, IR)

Access the full session

Session thumbnail
Hypertrophic cardiomyopathy and the spectrum of left ventricular hypertrophy

The Event

Event poster

ESC Congress 2026

29 August 2026 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Effect of mavacamten on left atrial remodeling and function in obstructive hypertrophic cardiomyopathy. A real-world multicentric prospective study.
29 August 2026
thumbnail
Congress Presentation
Introduction
25 August 2023
thumbnail
Congress Presentation
Mavacamten in hypertrophic cardiomyopathy: use of accessible functional testing to examine real-world effectiveness
1 September 2025
thumbnail
Congress Presentation
Cardiac Myosin inhibitor improves mid-ventricular obstruction in hypertrophic cardiomyopathy
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources